Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Medical Properties Trust
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Eroding Hospital Demand And Tight Credit Will Hurt Rental Income
Key Takeaways Shifting healthcare delivery models and regulatory challenges threaten demand for hospital real estate and undermine stability of rental income and earnings. Elevated debt costs, tenant financial strain, and ongoing asset sales further weaken growth prospects and increase risks to cash flow and asset values.
View narrative
US$3.50
FV
15.7% overvalued
intrinsic discount
-12.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Mercury Systems
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Regulatory Burdens And Supply Chain Challenges Will Curtail US Defense Prospects
Key Takeaways Heavy reliance on U.S. defense spending and evolving regulations creates heightened revenue volatility and higher compliance costs for Mercury Systems. Increased competition and a shift to software-based defense solutions threaten the relevance and profitability of Mercury's current hardware-focused product offerings.
View narrative
US$37.16
FV
79.5% overvalued
intrinsic discount
4.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
6 days ago
author updated this narrative
Recursion Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
Key Takeaways High R&D spending and lack of commercial assets expose the company to negative cash flow, dilution, and earnings risk. Regulatory uncertainty, revenue instability from partnerships, and increasing competition jeopardize growth, margins, and long-term market potential.
View narrative
US$3.00
FV
92.3% overvalued
intrinsic discount
11.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
QuidelOrtho
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Debt And Costs Will Squeeze Margins As Markets Rebound
Key Takeaways Cost pressures and shifting reimbursement trends threaten long-term revenue growth and margin expansion, despite rising global demand for advanced diagnostics and planned operational improvements. Expansion into underpenetrated and emerging markets is challenged by government price controls and aggressive local competition, constraining sustainable revenue and margin gains.
View narrative
US$26.00
FV
0.3% undervalued
intrinsic discount
2.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Ambarella
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Geopolitical Strain And Chip Rivalry Will Undermine Future Value
Key Takeaways Geopolitical risks and industry shifts threaten supply chain stability, cost structure, and market position, leading to heightened unpredictability in revenues and margins. Growing competition and customer self-sufficiency undermine pricing power and profitability, while reliance on core markets and R&D spending heighten financial vulnerability.
View narrative
US$50.02
FV
33.9% overvalued
intrinsic discount
12.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
PTC Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Rising Healthcare Cost Containment And Delayed Approvals Will Erode Margins
Key Takeaways Increasing regulatory delays, pricing constraints, and competition threaten PTC's ability to profitably launch and sustain new rare disease therapies. Reliance on a shrinking product portfolio and persistent cash burn heighten the risk of revenue decline and potential shareholder dilution.
View narrative
US$44.00
FV
11.0% overvalued
intrinsic discount
-21.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Rumble
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Rising Regulatory Risks Will Stall Digital Evolution Yet Invite Recovery
Key Takeaways Elevated regulatory risks, slow international adoption, and brand hesitancy threaten Rumble's ability to scale revenues and diversify income sources. High infrastructure costs and niche audience could delay profitability, with entrenched competition potentially capping long-term margin expansion.
View narrative
US$10.00
FV
21.0% undervalued
intrinsic discount
24.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Ultragenyx Pharmaceutical
AN
AnalystLowTarget
Consensus Narrative from 20 Analysts
Rising Clinical Risks Will Depress Biotech Pipeline Yet Invite Rebound
Key Takeaways Ultragenyx's promising late-stage pipeline and orphan drug approvals face significant risks from clinical setbacks, pricing pressures, and high R&D costs, impacting future profitability. Heavy reliance on a limited product portfolio, potential biosimilar competition, and challenges in global commercialization threaten long-term revenue growth and margin expansion.
View narrative
US$37.94
FV
21.7% undervalued
intrinsic discount
14.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
PROCEPT BioRobotics
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
Key Takeaways Growth potential driven by demographic trends and innovation faces threats from competition, pricing pressure, and possible market shifts to non-device treatments. Expansion and recurring revenue are promising, but high costs, reimbursement risks, and geopolitical factors could constrain margins and profitability.
View narrative
US$51.00
FV
18.5% undervalued
intrinsic discount
26.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Value any company in seconds
Popular companies